Multi-Analyte Home Test - Empowering Consumers
This client is an early stage, clinical diagnostic company with a breakthrough technology to provide over 100 clinical diagnostic measurements from a few drops of blood for about US$35. The price will include online, interactive, multimedia sessions of 20-30 minutes customized to the health of the consumer. This will motivate the consumers to make healthy choices and will allow them and physicians to interact more effectively.
More importantly, having additional tests on this platform is very inexpensive and this platform will include large panels of research analytes that may not be clinically valid at present. This test will therefore create, for the very first time, unique scientific opportunities in the search of useful biomarkers that can signal the early onset of cancer and other diseases.
There is currently no other product or technology in the market that addresses the scope and capabilities of this company’s platform technologies. The maximum market potential of this product in the US alone is estimated at US $9.2 billion (285 million tests) per year for the consumer market. A much more conservative estimate pegs theUS annual consumer market at US$1.4 billion. The market potential however goes beyond the consumer’s market alone and covers a variety of other segments, including physician’s office market, drug testing market, and insurance testing market.
A New Platform – Ground-breaking Technology and Novel Delivery of Results
The heart of this technology platform is Fractionating Cascade Mass Spectrometry (FC/MS) that has the capability of delivering a comprehensive panel of blood tests from just a few drops of blood drawn by consumers. This is combined with novel blood collection device as well as novel delivery of results.
Collection of Blood – The Company will use an innovative blood collection kits that will be sold at local pharmacies. The kit will contain a plastic DVD-like disc that can fit into a CD/DVD-drive bay. The disc has capillary channels for collecting blood sample. When a finger is pricked, the blood drops are collected into a small hole on the disc and into the collection channel on the disc. When the channel is filled, it is covered up and the disc is placed into the drive bay and it starts spinning. The spinning forces the blood from the collection channel into the reservoirs that are designed to preserve the blood while the DVD is mailed to the Company for analysis. During the spinning process, the consumer will be directed to the Company’s website to the order form where it reads the registration number of the disc and collects the order and payment from the consumer.
The company will be akin to Netflix of Healthcare!
FC/MS Process – The FC/MS process allows the Company to efficiently and quickly analyze over a hundred analytes / test panels in a cost-effective manner from just a small quantity of blood. This is achieved because the technology uses:
a. Serial Fractionation – captures groups of molecules for detection without perturbing remaining molecules so that the remaining molecules can be captured in subsequent detection groups from the same sample.
b. Parellel Detection – multiple analytes are measured simultaneously thereby cutting on costs and time
c. Multiplexed Immunoglobins – massively multiplexed immnunoglobins quantification trivializes cost and througput
Results Delivery – This is another important feature of the technology. Results are be reported in a multimedia website, whose mission and promotion is to promotion of healthy choices. The website will explain the latest results and is customized to reflect the consumers’ health and their blood profile reports.
Product Right for Many Market Segments
Direct to consumer (DTC) diagnostic market (typically for tests where the consumer collects the sample and sends it to a lab for analysis) is currently relatively small (around US$100 million) out of a total of US$58 billion market for laboratory testing, but is growing at around 15 to 20% a year. This market is currently dominated by at-home genetic testing.
This market is ripe for growth and awaiting a break-through technology. This platform opens up such an opportunity wherein consumers can educate themselves, have a meaningful dialog with their doctors, and make healthy choices. The company’s own research indicates a potential maximum annual market in just this segment in the US at over US$9 billion for this product, and a conservative estimate at US$1.4 billion.
The company’s products will also find a big role in other healthcare markets including physician’s office, drug testing and insurance testing markets. Additionally, there will be possibilities of offering products such as personalized vitamins, and medicinal products. The company's technology is sparking interest from some of the largest companies in the world in consumer products and healthcare businesses.
Next Steps
Our client’s company is looking for strategic partners to take their technology to the next phase where it can find corporate licensing partnerships that will allow it to complete and market its products.
Contact Us
Do contact us for more information on this technology and to connect with our client.